Name : Mahmoud A.Al-Sha'er

Email:a.mahmoud@zu.edu.jo

IT/ CIS

Academic Rank: Professor

Membership:

1	Jordan Association

Qualifications:

1	BSc Pharmacy,1998, JUST
2	MSc Pharmacy; specialized in pharmaceutical sciences, 2000, UJ
3	PhD Pharmacy; specialized in Medicinal Chemistry and Drug Design, 2010, UJ

Professional Objective(s): Development of new anticancer agents using molecular modeling, research unit in molecular modeling, drug design, and lecturing in medicinal chemistry, Analytical chemistry, and synthetic chemistry, in addition to Lab administration

Teaching Experience:

#	From	to	Experience
1	2020	Till now	Full Professor in Medicinal Chemistry and Drug Design
2	2015	2020	Associate Professor in Medicinal Chemistry and Drug Design

3	2010	2015	Assistant Professor in Medicinal Chemistry and Drug Design
4	10-9-2010	Till now	Academic lecturer at faculty of pharmacy-Zarqa University
5	1/10/2006	1/7/2010:	Act as lecturer in the pharmaceutical department-faculty of pharmacy at Applied Science University- Amman (ASU). job description: Lecturer. - Topics covered are: Pharmacokinetics Lab, Microbiology I and II Lab, Analytical Chemistry, Medicinal Chemistry, Pharmacognosy, Pharmacy Ethics, Pharmaceutics Lab, Physical Pharmacy Lab, Industrial Lab.
6	14/12/2002	30/6/2006	Education, teaching, Coordination as a head section of pharmacy department in Al-Sebiae institute-Taif/ Kingdom of Saudi Arabia. -Job description: Pharmaceutical science Lecturer (head of pharmacy department)
7	14/12/2001	1/12/2002:	Work as researcher in the herbal section in Arab pharmaceutical company APM Using HPLC ,TLC, GC techniques. -Job description: Researcher.

Publications:

#	Title	Publisher	Year/ Issue (Vol/No)
1.	Investigation of Antimicrobial Sesquiterpenes in Ferula harmonis F. root	ACTA Technologie et lagis medicamenti	**2000**
2.	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay	European Journal of Medicinal Chemistry	**2010**
3.	Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90α Inhibitors	J. Chem. Inf. Model	**2010**
4.	Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation	J Enzyme Inhib Med Chem.	**2010**
5.	Rational exploration of new pyridinium-based HSP90α inhibitors tailored to thiamine structure	Medicinal Chemistry Research	**2012**
6.	Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors	Med Chem Res	**2012**
7.	Application of Docking-Based	Journal of Molecular Modeling	**2012**

	Comparative Intermolecular Contacts Analysis for Validating Hsp90α Docking Studies and Subsequent In Silico screening for Inhibitors		
8.	1-[2-Substituted ethyl]-2-methyl-5-nitroimidazole derivatives, synthesis andantibacterial activities	Der Pharma Chemica	**2013**
9.	Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors	Journal of molecular graphics & modelling	**2013**
10.	Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies	Der Pharma chemica	**2013**
11.	Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors,	The Open Medicinal Chemistry Journal	**2013**
12.	Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.	Journal of Molecular Modeling	**2014**
13.	Could the cancer be a chronic immune disorder? rather than a serious malignant disease	Der Pharma chemica	**2014**
14.	Discovery of nanomolar Phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modelling and virtual screening followed by in vitro analysis	European Journal of Medicinal Chemistry	**2014**
15.	Evaluation of antimicrobial activities of synthesized pyridinium derivatives	Der Pharma chemica	**2014**
16.	Docking and Pharmacophore Mapping of Halogenated Pyridinium Derivatives as Heat Shock Protein90	Journal of Chemical and Pharmaceutical Research	**2015**
17.	Screening of miscellaneous Hsp90 inhibitors using virtual co-crystallized pharmacophore	Journal of Computational Methods in Molecular Design	**2015**
18.	Discovery of Check Point Kinase1 (Chk1) Inhibitors as Potential Anticancer Agents Using Ligand-	Journal of In Silico & In Vitro Pharmacology	**2015**

	Based Modelling and Virtual Screening		
19.	Evaluation of Novel Akt1 Inhibitors as Anticancer Agents using Virtual Co-crystallized Pharmacophore Generation	J Mol Graph Model.	**2015**
20.	Discovery of new heat shock protein 90 inhibitors using virtual co-crystallized pharmacophore generation	J Enzyme Inhib Med Chem	**2016**
21.	Discovery of novel potent nuclear factor kappa-B inhibitors (IKK-β) via extensive ligand-based modeling and virtual screening	J Mol Recognit.	**2016**
22	Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor	J Mol Graph Model	**2018**
23	Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis	Med Chem	**2019**
24	Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents	Comput Biol Chem	**2019**
25	Investigation of binding characteristics of Phosphoinositide-dependent kinase-1 (PDK1) co-crystallized ligands through virtual pharmacophore modeling leading to novel anti - PDK1 hits	Med Chem	**2019**
26	Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents	Anticancer Agents Med Chem	**2020**
27	Combined High Throughput Screening with QSAR Analysis Unravel Potential Glyoxalase-I inhibitors	Curr Comput Aided Drug Des	**2020**
28	Elaboration of Novel TTK1	Current Computer-Aided Drug	**2020**

	Inhibitory Leads via QSAR-Guided Selection of Crystallographic Pharmacophores Followed By In vitro Assay	Design	
29	Identification of the first “two digit nano-molar” inhibitors of the human glyoxalase-I enzyme as potential anticancer agents	Medicinal Chemistry	**2021**
30	Repurposing FDA-approved drugs against the "main protease" pivotal enzyme in COVID-19 virus using computer-aided drug design techniques	Preprint at Research Square	**2022**
31	Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores	Molecular Diversity	**2022**
32	Pharmacophore Modeling of Targets Infested with Activity Cliffs via Molecular Dynamics Simulation Coupled with QSAR and Comparison with other Pharmacophore Generation Methods: KDR as Case Study	Molecular Informatics	**2022**
33	Evaluation of antibacterial, antioxidant, cytotoxic, and acetylcholinesterase inhibition activities of novel [1,4] benzoxazepines fused to heterocyclic systems with a molecular modeling study	Medicinal Chemistry Research	**2022**
34	Novel Sulfonamide−Triazine Hybrid Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	ACS Omega	**2023**
35	Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand- based pharmacophores and biological screening	Medicinal Chemistry Research	**2023**
36	In Silico Evaluation of Ferulic Acid Based Multifunctional Conjugates as Potential Drug Candidates	Medicinal Chemistry	**2023**
37	Novel hydantoin derivatives: Synthesis and biological activity	Results in Chemistry	**2023**

	evaluation		
38	Docking, synthesis, and anticancer assessment of novel quinoline-amidrazone hybrids	Pharmacia	**2024**
39	Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer Protein	Current Computer - Aided Drug Design	**2024**
40	Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	ACS Omega	**2024**
41	Synthesis, complexation, in vitro cholinesterase inhibitory activities and molecular docking of azinethiacrown ethers and acyclic thiacrown ethers derived indole	Journal of Molecular Structure	**2024**

Books:

#	Book Title	Publisher	Year
1.	*Discovery and optimization of new anticancer agents*	Scholars' press	**2015**
2	*تصميم الادوية وبناؤها*	ناشر: مؤسسة الامة العربية للنشر والتوزيع المقر الرئيسي : جمهورية مصر العربية رقم الايداع القانوني : 23543/2018 الرقم الدولي: 4/476/783/977/978 جهة الايداع: وزارة الثقافة المصرية 2018 سنة النشر 1440 هـ- 2019	**2018**
3	*نظرة الى السرطان وطرق علاجه*	دار أسامة للنشر , عمان, Amazon	**2021**

Supervision of Theses:

#	Year	University	Thesis Title	Student Name
1.	*2017*	University of Jordan	Discovery and Optimzation of New KDR inhibitors	**Alaa Aziz**
2	*2020*	Zarqa University	Synthesis of triazines as anticancer agents	**Mahmoud Olimate**
3	*2021*	Zarqa University	Synthesis of Hydantoin derivatives as anticancer agents	**Abdel Wahhab Oqail**

4	*2023*	Zarqa University	Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents	**Omar Mahdi**
5	*2023*	Zarqa University	DESIGN OF AMINOBENZOXAZOLE DERIVATIVES AS KDR INHIBITORS AND ANTI-CANCER AGENTS	**Ali Khadir**
6	*2024*	Isra University	Design, synthesis, characterization, and in-vitro evaluation of novel depigmenting agents	**Amani Salman**

Personal Information

Name	Mahmoud A.Al-Sha'er			
Place and Date of Birth	Libya, 30/3/1976			
Nationality	Jordanian			
Marital Status	Married			
Address	Amman-Jabal Al-Nuzha			
Work Tel No.	065 5 38 211 00			
Mobile:	0786844928			
Postal Address	13132 P.O.Box 132222 Faculty of Pharmacy	Zarqa University-Zarqa		